Compare iShares Global Clean Energy ETF (ICLN) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Eli Lilly And Co — how do they compare? iShares Global Clean Energy ETF trades at $17.23 (market cap $2.27B), while Eli Lilly And Co trades at $1,169.35 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 458.1× iShares Global Clean Energy ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares Global Clean Energy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and Eli Lilly And Co for 93 Days on average.
| ICLN | LLY | |
|---|---|---|
Market Cap | $2.27B | $1.04T |
Volume | 6,845,064 | 3,064,878 |
52-Week High | $23.75 | $1.28K |
52-Week Low | $15.78 | $799.57 |
Typical Hold Time | 87 Days | 93 Days |
Sector | — | Health |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.31, down 1.31% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF's financial ratios are unavailable in the provided data, but recent news highlights its focus on global clean energy with 105 holdings and a 0.38% expense ratio. It faces volatility, with a 57.2% maximum drawdown noted in comparisons against traditional energy ETFs.
The outlook for ICLN is mixed; geopolitical tensions and global renewable energy investments provide tailwinds, but high volatility and competition from fossil fuel ETFs pose risks. Investors should weigh its growth potential against expense ratios and performance consistency in the evolving energy sector.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
